Medios AG, a leading provider of Specialty Pharma in Europe, announced the appointment of Katrin Neuffer as Director Investor Relations & Communications, effective immediately. Neuffer will oversee the company's communications with investors, analysts, the media, and the public. She succeeds Claudia Nickolaus, who has led the department and will be handing over leadership to Neuffer.
Neuffer brings around 20 years of experience in capital markets communications. She began her career at an Investor Relations agency and then served as Head of Investor Relations & Corporate Communications at SDAX-listed Wacker Neuson SE from 2007 to 2018, guiding the company from its IPO through its establishment as a consistently attractive investment. She also led the Strategy and Sustainability departments there. Subsequently, she headed an international 20-member team as Vice President Investor Relations & Corporate Communications and Marketing at the Exyte Group (formerly M+W Group), where she was responsible for preparing an IPO with a targeted market capitalization of more than EUR 2 billion. Since 2020, she has worked as an independent consultant for publicly listed companies in investor relations, IPO preparation, and crisis and restructuring communications.
Claudia Nickolaus played a key role in building and shaping Medios' Investor Relations activities, from financial reporting and ESG communications to the company's first Capital Markets Day in 2022. Prior to joining Medios, she held senior Investor Relations positions at publicly listed companies, including Merck KGaA.
Thomas Meier, CEO of Medios AG, expressed his enthusiasm for the appointment: "With Katrin Neuffer, we are gaining a proven capital markets expert who has guided publicly listed companies through decisive phases of development, from IPOs to strategic repositioning. Her experience will help us reposition Medios in the capital markets and intensify our dialogue with investors, analysts, and the media." He also extended sincere gratitude to Claudia Nickolaus for her many years of dedication and professionalism in shaping Medios' capital markets communications.
The announcement comes ahead of several key events for the Medios Group in the 2026 financial year. On August 12, the company will release its Half-Year Financial Report 2026. From September 21 to 23, Medios will participate in the Berenberg and Goldman Sachs 15th German Corporate Conference in Munich. On September 28 and 29, the company will host its Medios Capital Markets Day. The quarterly statement as of September 30, 2026, will be published on November 10.
Medios AG is a leading provider of Specialty Pharma in Europe, with locations in Germany, the Netherlands, Belgium, and Spain. The company supports key partners in the supply chain with innovative solutions and intelligent services. Medios focuses on pioneering individualized medicine to make the most innovative therapies available to everyone, collaborating with pharmacies, specialist practices, and pharmaceutical companies. As Germany's first listed specialty pharmaceutical company, its shares (ISIN: DE000A1MMCC8) are listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and are included in the SDAX selection index. More information can be found at www.medios.group.
